2-(difluoromethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine | 1425334-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(difluoromethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• CAS: 1425334-94-6
• 化学式: C₁₂H₁₆BF₂NO₃
• 分子量: 271.072
• InChiKey: SHGGVOUSQKPBDQ-UHFFFAOYSA-N

物化性质

• 沸点：
  327.2±42.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.98
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(difluoromethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 在 sodium carbonate 、 三氟乙酸 作用下， 以 Petroleum ether 为溶剂， 生成 3-(2-(difluoromethoxy)pyridin-3-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
  参考文献：
  名称：

  SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF

  摘要：

  The disclosure provides for small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. The disclosure further provides methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.

  公开号：

  US20230183210A1
• 作为产物：
  描述：

  3-溴-2-羟基吡啶 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 potassium acetate 、 sodium sulfate 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 32.33h， 生成 2-(difluoromethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
  参考文献：
  名称：

  SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF

  摘要：

  The disclosure provides for small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. The disclosure further provides methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.

  公开号：

  US20230183210A1

文献信息

• PYRROLOPYRIMIDINES AS CFTR POTENTIATORS
  申请人：CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.

  公开号：US20180141954A1

  公开（公告）日：2018-05-24

  The present invention relates to compounds of Formula I, wherein R 1a , R 1b , R 2 , R 3 , R 4 , W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

  本发明涉及式I的化合物，其中R1a、R1b、R2、R3、R4、W、Y和Z如本文所述，并且其药学上可接受的盐。这些化合物是囊性纤维化跨膜传导调节器（CFTR）的增效剂。本发明还揭示了包括该化合物的药物组合物，可选地与额外治疗剂结合，并通过给予这些化合物来增强哺乳动物（包括人类）CFTR的方法。这些化合物可用于治疗囊性纤维化（CF）、哮喘、支气管扩张、慢性阻塞性肺病（COPD）、便秘、糖尿病、干眼症、胰腺炎、鼻窦炎、Sjögren综合征和其他与CFTR相关的疾病。
• [EN] PURINE DERIVATIVES AS ANTICANCER AGENTS<br/>[FR] DÉRIVÉS DE PURINE UTILISÉS EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：TANGO THERAPEUTICS INC

  公开号：WO2022197892A1

  公开（公告）日：2022-09-22

  Compounds are provided according to Formula (I). Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, tautomers and. stereoisomers, as well as pharmaceutical compositions, wherein Ring B, Ring A, RA, Rb, Rc, Rc', R1, R2, R6, m and n are as defined herein. The compounds disclosed herein are contemplated to be useful for the prevention and treatment of a variety of conditions.

  化合物按照公式（I）提供。公式（I），以及药学上可接受的盐，水合物，溶剂物，前药，互变异构体和立体异构体，以及药物组成物，其中环B，环A，RA，Rb，Rc，Rc'，R1，R2，R6，m和n如本文所定义。本文所披露的化合物被认为对预防和治疗多种疾病有用。